Sam Altman Says the Singularity Is Here. The Evidence Suggests Otherwise
AI keeps getting more capable, but capability isn’t the same thing as intelligence. Here’s why the race toward AGI may be hitting a ceiling few want to acknowledge.
Similar Posts
Lucid dismisses report it was weighing bankruptcy after shares plunge
A Lucid Air electric vehicle (EV) at the company’s showroom in Tysons, Virginia, US, on Saturday, Feb. 17, 2024. Samuel Corum | Bloomberg | Getty Images Lucid Motor stock fell more than 40% at one point and trading was halted for volatility multiple times Tuesday amid speculation that the company is considering new options. A…
PRA consults on updated guidance for friendly society amalgamations and transfers
News release Financial mutuals play an important role in the UK financial services sector, and the PRA is committed to supporting their long-term, sustainable growth and ability to compete effectively alongside other firms. In the PRA/FCA Mutuals Landscape Report, the PRA highlighted its plan to provide guidance on the Part VIII transfer process. The proposed changes…
Finance teams spend 13 hours a week verifying AI outputs: Trial Balance
Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. The Trial Balance is CFO.com’s weekly preview of stories, stats and events to help you prepare. Part 1 — Finance teams are losing some productivity gains verifying AI outputs, according to IDC-Sage report Artificial intelligence tools have…
AMC’s Popcorn Bucket Business Is Now Worth $100 Million
Seven years ago, nobody was talking about popcorn buckets as a business. Now AMC says they’ll bring in $100 million this year alone, nearly double what the theater chain made in 2023, the New York Times reports. Limited-edition, movie-themed buckets are the stars here, not the buttery popcorn. They can sell for as much as…
EY reports data breach on IT support ticket platform: Trial Balance
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. The Trial Balance is CFO.com’s weekly preview of stories, stats and events to help you prepare. Part 1 — In the wake of a breach this spring, EY says its “systems are now secure.” EY says an…
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here’s what happens next.
The FDA is deciding whether seven peptides can be legally compounded, potentially opening the door to broader use in Americans.
